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Abstract: Tauopathies are a group of neurodegenerative diseases characterized by the pathological aggregation of 
the microtubule-associated protein tau. These include more than 20 diseases, with Alzheimer’s disease being the 
most frequent. While pathological and neurotoxic effects of tau are well documented, the mechanisms by which 
tau can promote neurodegeneration are less clear. Increasing evidence suggests a functional role for microRNAs in 
the pathogenesis of tauopathies, with altered expression and function of microRNAs in experimental models and 
patient brain. To determine whether a pathological expression of tau leads to altered microRNA expression, we in-
vestigated a mouse model (VLW), which overexpresses tau carrying three mutations identified in patients suffering 
from frontotemporal dementia with parkinsonism-17. Argonaute-2-bound microRNAs were co-immunoprecipitated 
using hippocampal tissue to identify active microRNAs within the model and quantified using a genome-wide high-
throughput qPCR-based microRNA platform. While similar numbers of microRNAs are present between wild-type 
and VLW mice, a prominent increase in Argonaute-2-bound levels of microRNAs could be observed in VLW mice. 
This included microRNA-134, microRNA-99a and microRNA-101. Subsequent experiments revealed this increase in 
Argonaute-2 loading of microRNAs to correlate with increased microRNA expression. Our in vivo study suggests that 
a pathological tau overexpression may lead to an increase in active microRNAs, possibly contributing to dysregula-
tion of gene expression and tau-induced pathology.
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Introduction
Tauopathies are a family of neurodegenerative 
disorders featuring a prominent tau neurofibril-
lary pathology [1]. Alzheimer’s disease (AD) is 
the most common tauopathy; there are, how-
ever, many others including familial frontotem-
poral lobar degeneration, Pick’s disease, pro-
gressive supranuclear palsy, and corticobasal 
degeneration [1]. Huntington’s disease has 
also recently been described as a tauopathy 
[2]. Frontotemporal dementia and parkinson-
ism linked to chromosome 17 (FTDP-17) is a 
unique example of a tauopathy induced purely 
by mutation(s) to the tau gene, resulting in tau 
aggregation with a complete absence of the 
amyloid-β deposition and other co-morbidities 
which regularly accompany tauopathies and 
associated disorders [3].
Tau is a microtubule-associated phosphopro-
tein, which is mainly found in mature neurons, 
where it is enriched in the axonal compartment. 
Tau is encoded by a single gene (MAPT) on 
chromosome 17, giving rise to six major iso-
forms containing either three (3R) or four (4R) 
microtubule-binding domain repeats [4]. The 
main function of tau includes the stabilization 
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of microtubules [4]. Tau is, however, involved in 
a myriad of different functions including axonal 
transport [5] and the induction of long-term 
depression (LTD) [6]. Tau is subject to various 
post-transcriptional modifications, including 
phosphorylation, glycation, ubiquitination and 
truncation among others, with tau phosphoryla-
tion the best characterized [4]. In tauopathies, 
tau becomes abnormally hyperphosphorylated. 
This hyperphosphorylated form causes tau to 
detach from the microtubules, to accumulate in 
the cytoplasm forming insoluble filaments and 
tau aggregates [7]. Despite hyperphosphory-
lated tau having a highly destructive effect on 
neurons [5], the exact neurotoxic mechanisms 
caused by tau remain unclear, however, numer-
ous putative mechanisms have been proposed. 
Among many others, these include the loss-of-
function as a stabilizer of microtubule struc-
tures in the axon, leading to depolymerization, 
the formation of insoluble aggregates which 
damage the cytoplasm and axonal compart-
ment or the formation of tau oligomers inducing 
synaptic dysfunction [5, 8, 9]. Delineating the 
actions of tau within these diseases is of great 
interest, not only for understanding tauopa-
thies, but also a plethora of other neurological 
disorders within which tau undergoes abnor- 
mal regulations such as the neurological dis-
ease, epilepsy, in which tau contributes to an 
increased state of hyperexcitability [10, 11].
MicroRNAs (miRNA) are short non-coding RNAs 
which function to regulate protein expression at 
a post-transcriptional level [12]. Dysregulation 
of miRNA contributes to the pathogenesis of 
numerous brain diseases including tauopa-
thies [13]. MiRNAs are well established as criti-
cal molecules within the cell. In the central ner-
vous system (CNS), miRNAs influence numer-
ous pathways, including neuronal function, 
dendrite outgrowth and development [14, 15]. 
MiRNAs function within an RNA-induced silenc-
ing complex (RISC) to inhibit translation or 
degrade targeted mRNA transcripts [12]. After 
the initial processing by the type III RNA poly-
merase, Dicer, which cleaves the pre-miRNA 
into its mature state, miRNAs are bound by the 
endonuclease Argonaute-2 (Ago-2), a key pro-
tein within the RISC complex. The loaded miRNA 
sequence then guides RISC to target compli-
mentary mRNA transcripts to degrade or inhibit 
translation of the mRNA. This mechanism of 
complimentary sequence-targeting enables a 
single miRNA to target and regulate multiple 
transcripts and potentially entire pathways 
[16].
The integral role miRNAs play in tau regulation 
has been demonstrated in numerous studies. 
Genetic ablation of DICER in mice led to a 
reduction of miRNAs, which correlated directly 
with an increase in tau phosphorylation and 
neurodegeneration and which was primarily 
attributed to the loss of miR-15a [17]. Upre- 
gulation of miR-146a in AD mouse models 
resulted in increased phosphorylation of tau 
by the targeting of rho-associated, coiled-coil-
containing protein kinase 1 (ROCK1) [18]. MiR-
219 was shown to target tau transcripts and 
is reduced in AD and tangle-predominant 
dementias patient brains, with reduction of 
miR-219 resulting in exacerbated tau toxicity in 
Drosophila models and mammalian cell cul-
tures [19]. Actual investigations into the miRNA 
expression of tauopathy patients, with the 
exception of AD [20, 21], have been limited to 
progressive supranuclear palsy, a rare disease 
characterised by the presence of neurofibrillary 
tangles (NFTs) composed of tau sharing many 
characteristics with FTDP-17 [3, 22, 23]. How- 
ever, despite the apparent interest on the 
impact of miRNA on tau with investigations in 
Drosophila, AD mouse models and even tauop-
athy patients, there has not been a study of 
active Ago-2-bound miRNAs within tau path- 
ology.
In the present study we used a high-throughput 
PCR-based platform to screen Ago-2-bound 
miRNA in wild-type (WT) and mice overexpress-
ing mutated tau carrying three FTDP-17 muta-
tions (VLW) [24]. Results suggest an overall 
increase in miRNA-loading to the RISC which 
may promote excessive miRNA-based silencing 
of target transcripts. Our results therefore pro-
pose a tau-driven activation of miRNAs and 
increases in miRNA expression, further sug-
gesting targeting of tau as a therapeutic strat-
egy to treat brain diseases with an underlying 
tauopathy.
Material and methods
Animals
All animal procedures were performed in 
accordance with the principals of the European 
Communities Council Directive (86/609/EEC) 
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and National Institute of Health’s Guide for 
the Care and Use of Laboratory Animals. All 
studies involving animals were approved by the 
Research Ethics Committee of the Centro de 
Biología Molecular Severo Ochoa Institutional 
Animal Care and Utilization Committee (Comité 
de Ética de Experimentación Animal del CBM, 
CEEA-CBM), Madrid, Spain (PROEX293/15). 
Animal housing and maintenance protocols fol-
lowed the guidelines of the Council of the 
European Convention ETS123 and were per-
formed in accordance with the principals of the 
European Union adopted Directive (2010/63/
EU). VLW transgenic mice overexpress a human 
4-repeat tau isoform carrying three FTDP-17 
mutations (G272V, P301L and R406W) under 
the thy1 promoter [24]. The tau mutations 
G272V and P301L are both located within the 
microtubule binding repeats, thereby disrupting 
binding of tau to the microtubules leading to a 
reduction in microtubule assembly, with each 
affecting a specific tau isoform (3R and 4R) 
[25]. The R406W mutation is located at the 
C-terminus end of the molecule. This mutation 
in tau has been shown to lead to an increase in 
tau phosphorylation which is a prominent fea-
ture in tauopathies [25]. The combination of 
these mutations in tau induces both the loss of 
function of tau in 3R and 4R isoforms as well 
as tau hyperphosphorylation typical of tauo- 
pathies, aiming in this way for a synergistic 
pathological effect in transgenic VLW mice. 
Subsequent studies showed that these mice 
present an increase in hyperexcitability states 
and experience spontaneous epileptic seizures 
[10], an increase in acetylcholinesterase levels 
and activity [26] and early-onset deterioration 
of γ-aminobutyric acid (GABA)ergic septohippo-
campal innervation [27]. All transgenic mice 
are bred under a C57Bl/6 background and only 
heterozygous VLW mice were used. Hippocampi 
were extracted from four months old eutha-
nized VLW and age matched C57Bl/6 WT con-
trol mice, immediately put on dry ice and stored 
for further processing. 
Ago-2 (mi) RNA-immunoprecipitation (RIP)
Ago-2 immunoprecipitation was carried out as 
previously reported using RNase free solutions 
[28]. Briefly, hippocampi obtained from VLW 
and control WT mice were homogenized manu-
ally using an immunoprecipitation buffer con-
taining 300 mM NaCl, 5 mM Mg2Cl, 50 mM Tris 
HCl (pH = 7.5), 0.1% NP-40, proteases inhibi-
tors Arotinin and Leupeptin (Merck, Darmstadt, 
Germany) and phosphatases inhibitors (PMSF 
(Roche, Basel, Switzerland) and vanadate 
(Merck, Darmstadt, Germany)). Nucleus, cell 
debris and membranes were removed by cen-
trifugation at 16,000× g for 15 min at 4°C. 
Supernatant was removed and considered as 
the total cell lysate. Then, 5 μg of Ago-2 anti-
body (Cat number: C34C6, Cell Signaling 
Technology, Danvers, MA, USA) was added to 
400 μg of the protein lysate and incubated 
overnight at 4°C in a carousel. The following 
day, 20 μl of a 50% protein-A/G-agarose bead 
solution (Santa Cruz Biotechnology, Heidelberg, 
Germany) was added to the samples, mixed 
and incubated for 1 h at 4°C. Finally, beads 
were centrifuged and pellet washed twice with 
immunoprecipitation buffer followed by Trizol 
extraction as previously described [28, 29].
MicroRNA profiling by OpenArray
MiRNA profiling was performed using the 
OpenArray platform from Thermo Fisher (Wal- 
tham, Massachusetts, United States), as de- 
scribed previously [28, 30]. Briefly, the Op- 
enArray reverse transcription reaction was per-
formed according to the manufacturer’s proto-
col using 3 µl of total RNA obtained from Ago-2 
immunoprecipitation. Before loading onto the 
OpenArray, cDNA was pre-amplified following 
the manufacturer’s recommendation. Then, the 
PreAmp product was diluted with 0.1X TE (1/40) 
and 22.5 µl of diluted PreAmp product was 
added to the same volume of 2X TaqMan 
OpenArray Real time PCR Master Mix (Cat No. 
4462164, AB). Finally, the mix of Pre-Amp prod-
uct and Master-Mix was loaded onto a 384-well 
OpenArray plate. OpenArray panels were auto-
matically loaded by the OpenArray AccuFill 
System (Thermo Fisher, Waltham, Massachu- 
setts, United States). Each panel enables the 
quantification of miRNA expression of three 
samples and up to four panels can be cycled 
simultaneously. Samples were randomized be- 
tween panels and run simultaneously on a 
QuantStudio 12K Flex Real-Time PCR system. 
754 mouse miRNAs were amplified from each 
sample together with 16 replicates of four inter-
nal controls (ath-miR159a (negative control), 
RNU48, RNU44 and U6 rRNA). The number of 
miRNAs identified in each sample was: 165 for 
WT1, 151 for WT2, 140 for VLW1, 210 for VLW2 
and 258 for VLW3. Only miRNAs which were 
expressed in all samples were used for further 
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analysis, totaling 87 miRNAs. Data was normal-
ized using a global normalization method where 
each Ct value was normalized to the geometric 
median of all Ct values in one sample. MiRNA 
expression was calculated using the 2-ΔΔCT 
method, using the average of the ΔCt values of 
WT1 and WT2 as a reference. Due to the low 
numbers, no statistical test has been carried 
out on the OpenArray and results are based on 
fold-changes between conditions. The heat 
map and Volcano plot were generated using 
ExpressionSuite Software Version 1.0.3 
(Thermo Fisher, Waltham, Massachusetts, Unit- 
ed States).
Quantitative polymerase chain reaction (qPCR)
MiRNA qPCR was carried out as previously 
described [29]. Briefly, 1 µg of total RNA was 
reverse transcribed using stem-loop Multiplex 
primer pools (Thermo Fisher, Waltham, Mass- 
achusetts, United States). Retro transcriptase 
(RT)-specific primers for the mouse miRNAs 
miR-134 (ID: 001186), miR-101 (ID: 002253), 
miR-99a (ID: 000435), miR-15b (ID: 000390) 
and miR-212 (ID: 002551) were used (Thermo 
Fisher, Waltham, Massachusetts, United Stat- 
es) and qPCRs were carried out on a Quant- 
Studio 12k Flex Real Time System (Thermo 
Fisher, Waltham, Massachusetts, United Stat- 
es) using Taqman miRNA assays (Thermo Fish- 
er, Waltham, Massachusetts, United States). 
RNU6 was used for normalization. The relative 
fold change in expression was calculated using 
the 2-ΔΔCT method [31].
Western blotting
Western blotting was performed as described 
previously [32]. Following quantification of pro-
tein concentration, 30 µg of protein samples 
were boiled in gel-loading buffer and separated 
by sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE). Proteins were 
transferred to nitrocellulose membranes and 
probed with the following primary antibodies: 
Argonaute-2 (Cell Signaling Technology, Dan- 
vers, MA, USA) and β-Actin Merck (Darmstadt, 
Germany). Next, membranes were incubated 
with horseradish peroxidase-conjugated sec-
ondary antibodies (Isis Ltd, Bray, Ireland) and 
protein bands visualized using chemilumines-
cence (Pierce Biotechnology, Rockford, IL, 
USA). Gel bands were captured using a Fujifilm 
LAS-3000 (Fujifilm, Tokyo, Japan) and analyzed 
using Alpha-EaseFC4.0 software.
Statistical analysis
Graphs were generated using GraphPad PrismTM 
software. For individual PCRs, all statistical 
analysis was performed on SPSS. Measures of 
significance between groups were tested by 
Mann-Whitney (non-parametric t-test) because 
the data does not follow a normal distribution. 
Minimum measures of significance were set at 
P < 0.05. 
Results
Increased Argonaute-2 microRNA loading in 
FTDP-17 tau overexpressing mice 
To study the effects of a pathological tau over-
expression on miRNA function, we used a 
mouse model, which overexpresses human 
tau, carrying three mutations identified previ-
ously in patients suffering from FTDP-17 
(G272V, P301L and R406W (VLW)) [24, 25]. In 
this model, FTDP-17 tau expression is driven by 
the neuronal promoter thy-1 and transgene 
expression is largely restricted to neurons of 
the dentate gyrus (DG), the cornus ammonis 
(CA) 1 and CA3 subfield of the hippocampus 
and the neocortex. Transgenic tau expression 
can also be found in the striatum and spinal 
cord [24, 32], similar to what has been reported 
for patients suffering from FTDP-17 [33]. 
Notably, the VLW mouse model lacks tau aggre-
gates but shows increased levels of tau hyper-
phosphorylation. Tau filaments formed in the 
mouse display a pre-tangle appearance [24]. 
Overexpression of tau in the model is modest 
(~2.5 fold) compared to other tauopathy mod-
els such as P301S (~5.5 fold) [34], with the 
phenotype more likely to be derived from abnor-
mal tau interactions than the formation of insol-
uble aggregates [24]. 
To elucidate the influence of pathological 
mutated FTDP-17 tau expression on miRNA 
activity, Ago-2-bound miRNAs were co-immuno-
precipitated from the hippocampi of FTDP-17 
tau overexpressing mice (VLW) and matched 
WT controls. Ago-2-bound miRNA content was 
analyzed by a custom OpenArray system [28], a 
high density qPCR assay plate enabling an- 
alysis of hundreds of custom reprinted select- 
ed miRNAs with a high reproducibility [35]. 
Genome-wide miRNA profiling was performed 
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using the OpenArray platform to identify func-
tional Ago-2-loaded miRNAs (Figure 1A). 
OpenArray was carried out on 2 WT and 3 age-
matched VLW mouse brains. Due to the low 
number of samples, no statistical testing was 
performed on the OpenArray data. Instead, 
miRNAs were selected for further experiments 
based on fold-change.
While a similar number of unique miRNA tran-
scripts seem to be uploaded onto Ago-2 in both 
WT and VLW mice (WT: 158±7.0; VLW: 202.1± 
34.26) (Figure 1B), the concentration of these 
uploaded miRNAs were increased in VLW mice, 
with 78 miRNAs being upregulated and only a 
single miRNA down-regulated (Figure 1B-D and 
Table 1). Among altered miRNAs, 15 were iden-
tifed within VLW mice with higher levels of 
Ago-2 loading (>26 Ct) and significant changes 
from control (>5 RQ) (Table 1). This includes 
Let-7c, miR-125a, miR-223, miR-193b, miR-
409-3p, miR-125b-1-3p, miR-134, miR-125b, 
miR-380-5p, miR-128a, miR-99a, miR-101, miR- 
544, miR-140 and miR-532-3p. No significant 
change in Ago-2 expression could be observed 
in the hippocampus between VLW and WT mice 
(Figure 1E) suggesting that increased Ago-2 
levels are not responsible for the observed 
increase of Ago-2 miRNA loading.
Our results suggest, therefore, that a patholo- 
gical overexpression of mutant FTDP-17 tau 
Figure 1. Argonaute-2-bound miRNA profiling in FTDP-17 tau overexpressing mice. A. Heatmap of differentially ex-
pressed miRNA in the hippocampus of WT and VLW mice profiled on OpenArray, each row representing an individual 
miRNA and each column representing an individual sample (n = 2 (Control (WT)) and 2 (VLW)). Expression ratio 
indicated by colour from green (low) to red (high) with intensity of expression indicated by scale bar. B. Graph show-
ing similar numbers of miRNAs identified by OpenArray to be bound to Ago-2 between WT and VLW mice. C. Graph 
showing increased levels of miRNAs in VLW mice bound to Ago-2 when compared to WT control mice (87 miRNAs 
are consistently expressed across all conditions and samples, among these 79 are differentially expressed from 
control with 78 upregulated (1.5-fold expression or greater) and 1 downregulated (0.75-fold expression or less). D. 
Volcano blot showing the distribution of miRNAs according to p value (Y axis) and fold changes (X axis). E. Represen-
tative Western blot (n = 1 per lane) and graph showing no significant difference in Argonaute-2 (Ago-2) expression 
in the hippocampus between WT and VLW mice (n = 5 per group; P = 0.354).
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leads to an increase in Ago-2 loading of miR-
NAs, possibly increasing miRNA activity.
Increased hippocampal expression of 
Argonaute-2-bound microRNAs in FTDP-17 tau 
overexpressing mice
Our results indicate that a suprisingly large 
number of miRNAs seemed to be upregulated 
within the Ago-2 complex in the hippocampus 
of FTDP-17 VLW mice. Ago-2 binding has been 
previously shown to correlate with miRNA ex- 
pression [36] and tau has been shown to alter 
the expression and activity of a variety of differ-
ent transcritpion factors [4, 37]. To determine 
whether tau pathology leads to an increase in 
miRNA expression and whether this correlates 
with the observed increase in Ago-2 binding, we 
selected five miRNAs to be analyzed in an extra 
set of mice. These miRNAs were selected 
according to their consistent expression on the 
OpenArray across all conditions or previous 
links to the pathogenesis of tauopathies. We 
quantified, by indiviual RT-qPCR, three of the 
most strongly upregulated and consistently 
expressed miRNAs on all samples analyzed by 
the OpenArray (miR-134 (7.9 fold change), miR-
99a (7.0 fold change) and miR-101 (6.5 fold 
change)) (Table 1), which have previously been 
associated with tauopathies and neurological 
disorders [29, 38, 39]. Despite miR-15b only 
showing a modest increase of 2.7, we decided 
to evaluate whether miR-15b was also regulat-
ed in our mouse model, because data has dem-
onstrated that miR-15b represses the expres-
sion of the β-sectretase BACE1 [40]. Finally, we 
analyzed miR-212, a miRNA that was stably 
expressed across FTDP-17 VLW mice and WT 
control at comparable levels. MiR-134, miR-
99a and miR-101 showed significantly higher 
expression in the hippocampus of FTDP-17 tau 
overexpressing mice compared to WT control 
mice, mirroring the OpenArrray Ago-2 results 
(Figure 2A-C). Although miR-15b lacked a sig-
nificantly elevated change from control, it 
showed a strong trend towards elevated expres-
sion in VLW mice (Figure 2D). Again, this mir-
rors the OpenArray and demonstrates that 
even minor differences detected by the Open- 
Array within the Ago-2 complex mimicked 
changes in miRNA expression at a cellular level. 
As predicted from our OpenArray results, miR-
212 showed no change between conditions 
(Figure 2E).
Our results, therefore, show that increased 
Ago-2 loading of miRNAs correlates with an 
increase in total expression of miRNAs and fur-
ther confirms that increased miRNA expression 
seems to be the general response to pathologi-
cal FTDP-17 tau overexpression.
Discussion
The main findings of the present study suggest 
that a pathological overexpression of FTDP-17 
tau in the hippocampus leads to an increase in 
hippocampal miRNA expression and Ago-2 
miRNA loading, possibly leading to more active 
miRNA and a reduction in miRNA-targeted 
genes which may contribute to tau-induced 
pathology.
Table 1. Differentially regulated miRNAs bound to Ago-2 in VLW mice
Relative abundance Ago-2-bound miRNAs altered in VLW mice (fold change)
UP in VLW (>5 fold change) Let-7c (25.4), miR-125a-5p (19.7), miR-223 (12.4), miR-193b (11.6), miR-409-3p (10.0), miR-125b-1-3p (9.9), 
miR-134 (7.9), miR-125b (7.9), miR-380-5p (7.3), miR-128a (7.1) miR-99a (7.0), miR-101 (6.5), miR-544 (6.4), 
miR-140 (5.5), miR-532-3p (5.2)
Up in VLW (>1.5 fold change) miR-100 (4.4), miR-26b (4.3), miR-26a (4.1), miR-192 (4.1), miR-672 (4.1), miR-135b (4.0), miR-384-5p (3.8), 
miR-434-3p (3.8), miR-30c (3.8), miR-320 (3.7), miR-323-3p (3.6), miR-421 (3.5), miR-872* (3.5), miR-19b 
(3.5), miR-99b (3.5), miR-376a (3.5), miR-30e (3.3), miR-331 (3.3), miR-138 (3.2), miR-184 (3.2), miR-434-5p 
(3.1), miR-539 (3.1), miR-106a (3.0), miR-1274 (3.0), miR-137 (3.0), miR-376b* (3.0), miR-136 (3.0), miR-376c 
(3.0), miR-222 (3.0), miR-218 (3.0), miR-126 (2.9), miR-487b (2.9), miR-484 (2.9), miR-186 (2.9), miR-410 (2.8), 
miR-744 (2.8), miR-16 (2.8), miR-411 (2.8), miR-1897-5p (2.7), miR-15b (2.7), miR-146b (2.6), miR-324-3p (2.4), 
miR-1937 (2.4), miR-139-3p (2.4), miR-9* (2.3), miR-433 (2.3), miR-150 (2.3), miR-146a (2.1), miR-2134 (2.1), 
miR-7a* (2.0), miR-191 (2.0), miR-720 (2.0), miR-7* (1.9), miR-877 (1.9), miR-664 (1.9), miR-2146 (1.9), miR-
204* (1.8), miR-491 (1.8),  miR-204 (1.6), miR-140-3p (1.6), miR-375 (1.6), miR-574-3p (1.6), miR-93* (1.6)
Unchanged (1.5-0.75) miR-212 (1.5), miR-592 (1.4), miR-1839-3p (1.4), miR-125b-2-3p (1.3), miR-448 (1.1), miR-1937c (1.0), miR-
1839-5p (1.0), miR-339-3p (1.0)
Down in VLW (< 0.75) miR-29b* (0.6)
Differentially regulated miRNAs bound to Ago-2 in VLW mice. MiRNAs bound to Ago-2 are listed based on decreasing levels of relative abundance. Fold change observed 
in OpenArray are listed within brackets for each individual miRNA. (*) denotes a distinct miRNA produced from the opposite-3’/-5’ arm of the same precursor as the 
original miRNA.
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mouse models, a recent study profiled miRNA 
expression in an AD mouse model overexpress-
ing mutant amyloid precursor protein (APPSWE) 
and mutant presenilin- 
1 (PS1) (APP/PS1) [21]. Among the miRNAs 
which were differentially expressed within the 
Figure 2. Quantification of miR-
NAs by individual RT-qPCR. Gra- 
phs showing relative expression 
of OpenArray analysis (n = 2 (WT) 
and 3 (VLW)) and RT-qPCR (n = 5 
(WT) and 6 (VLW)) in hippocampal 
tissue on selected miRNAs: miR-
134 (A), miR-99a (B), miR-101 
(C), miR-15b (D) and miR-212 (E). 
OA = OpenArray, IP = immunopre-
cipitation, *P < 0.05, **P < 0.01.
Whereas previous studies an- 
alyzing the miRNA profile of 
tauopathies focused on the 
expressional response of miR-
NAs [20-23], our study repre-
sents a novel investigation 
into miRNA regulation during 
tauopathy, specifically profil-
ing the active miRNA pool 
bound to Ago-2. Various stud-
ies have been undertaken to 
identify the miRNA profile dur-
ing tauopathies, with a partic-
ular emphasis on AD using 
both animal models and pati- 
ent brain [20, 21]. A previous 
study by Cogswell et al., using 
a RT-qPCR 96 well plate plat-
form, identified several dys-
regulated miRNA within the 
hippocampus of AD patients 
which were similarly identified 
in the VLW model including 
miR-125b, miR-100 and miR-
26a [41]. A subsequent study 
carried out by Lau et al., using 
deep sequencing of hippo-
campal and cortical brain tis-
sue from late onset AD show- 
ed upregulated miR-223 as 
another shared miRNA betwe- 
en patients and the mouse 
model [20]. It is possible that 
the alterations to these miR-
NAs within AD patients are 
driven by the same tau-based 
disruptions as within the VLW 
model and further study into 
the mechanism driving altera-
tions to these miRNAs could 
yield novel insights and thera-
peutic targets for the action of 
tau within AD. With regards to 
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APP/PS1 model, numerous miRNA shared a 
common trend of upregulation including Let-7c, 
miR-146a, miR-125a, miR-139, miR-433 and 
miR-320. This would indicate a similar response 
to the neuronal damage present in both mod-
els, but striking contrasts were also observed 
with miR-125b, miR-101 and miR-128a show-
ing downregulation within the APP/PS1 mouse 
model with all three miRNAs strongly upregu-
lated within the VLW model. These inverse 
patterns may indicate an alteration directly 
connected to distinct tau and amyloid-based 
pathology respectively. Notably, APP/PS1 mice 
were profiled with total miRNA rather than the 
Ago-2 bound miRNA as in our study, and com-
parison between these analyses must there-
fore take this into account. The expression pat-
terns of total miRNA has, however, been shown 
to directly correlate with the abundance of 
miRNA bound to Ago-2, thus the differential 
abundance of an Ago-2 bound miRNA is likely to 
directly correlate with total expression of the 
miRNA [36]. Probably representing the closest 
comparable study as regards to the miRNA 
transcriptome in the presence of pathological 
tau, a recent study analyzed miRNA expression 
in patients suffering from progressive supranu-
clear palsy which shares a similar pathology to 
FTDP-17 patients [22]. In this study, patients 
were analyzed using TaqMan Array MicroRNA 
cards recognizing 372 different miRNAs. The 
authors showed only four differentially expre- 
ssed miRNAs between control and patients 
(miR-147, miR-518e, miR-504 and miR-525-
3p). None of these miRNAs showed altered 
expression in the VLW model, probably due to 
the difference in the model used (e.g. mice vs 
patients or mutated tau vs no tau mutations). 
Interestingly, a previous study investigating the 
role of miRNAs in progressive supranuclear 
palsy and their role on tau splicing and the 
impact on the 4R:3R-tau ratio showed that 
miR-9 and miR-137, both significantly increased 
in the VLW model, can regulate the 4R:3R-ratio 
in neurons [23].
One of the main findings of our study is the 
strong increase in both expression and Ago-2 
loading of miRNAs in the VLW model. What 
causes the increase in miRNA expression and 
Ago-2 loading, we do not know. It is tempting 
to speculate that the increase in Ago-2 loading 
is a consequence of an increase in miRNA 
levels. Previous studies have shown miRNA 
expression to correlate with Ago-2 loading [36]. 
Whether the expression of mutant tau leads to 
an increase in the transcription of miRNAs is 
unclear. Pathological tau has been shown to 
increase the activity/expression of numerous 
transcription factors [4, 37], which may lead to 
the increased expression of miRNAs within 
cells. We also do not know what cell types con-
tribute to the increase in miRNA levels. This is 
possibly neurons, as mutated tau overexpres-
sion is driven by the neuronal thy-1 promoter. 
The contribution of glial cells, however, cannot 
be excluded and should be addressed in future 
experiments. Nevertheless, the increase in 
neuron-enriched miRNAs elevated in Ago-2-
bound miRNA, including the cluster miR-99a 
and Let-7c [42], the members of the miR-125 
family (miR-125a and miR-125b) [43], miR-134 
[44], miR-128 [45] and miR-101 [46] strongly 
suggest this to be neuronal. 
With neurodegeneration a common feature 
among all tauopathies [1], miRNAs capable of 
inducing or contributing to neurotoxicity were of 
particular interest. The miRNA cluster miR-99a 
along with Let-7c, contained within chromo-
some 21, shows a noticeable upregulation in 
the VLW mouse model. MiR-99a directly down-
regulates the transforming growth factor-β 
(TGF-β), which has key roles in WNT signaling 
and synaptic signaling [47]. Loss of TGF-β has 
been shown to increase neuronal cell death 
and microgliosis [48, 49]. Higher expression of 
Let-7c holds a unique neurodegenerative capa-
bility through activation of Toll-like receptors by 
functioning as an agonist [50]. Taken together, 
miRNAs within this cluster display destructive 
effects within neurological environments and 
are found at increased levels within several dis-
eases displaying cognitive impairments [39]. 
Therefore, their elevated activity within the VLW 
model may represent a key neurotoxic mecha-
nism induced by aberrant tau expression. 
Regulation of tau phosphorylation is a central 
characteristic of tauopathies [1]. MiR-125b has 
been shown to promote tau phosphorylation by 
targeting and downregulating tau phosphatas-
es dual specificity phosphatase 6 (DUSP6) and 
protein phosphatase 1, catalytic subunit, alpha 
isoform (PPP1CA) in mice [43]. MiR-125b has 
also been identified at elevated levels in AD 
patient brain [51]. 
Seizures and epileptiform activity have long 
been associated with the pathology of tauopa-
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thies [52]. In line with this, tau overexpressing 
VLW mice present increased hyperexcitability 
states [10]. However, how the expression of 
mutant tau induces this susceptibility to sei-
zures is unclear [10]. MiR-101 has been des- 
cribed as a critical regulator of excitation and 
inhibition within neural networks for developing 
a stable network. Transient blockading of miR-
101 in adult mice results in an impairment of 
hippocampal dependent cognition and block-
ade of miR-101 during early development res- 
ults in hyperexcitable networks in the mouse 
[46]. The targets of miR-101 include the Na-K-
Cl cotransporter (NKCC1), ankyrin-2 (ANk2) and 
kinesin like protein (Kifla), key proteins control-
ling synaptic outgrowth [46]. The increase of 
miR-101 in the VLW mice and its integral role in 
maintaining balanced signaling environment 
may be a contributing factor in the develop-
ment of the hyperexcitable phenotype in VLW 
mice [10] with higher levels of miR-101 po- 
tentially resulting in imbalances of inhibitory 
and excitatory neurons/inter-neurons. Another 
miRNA possibly leading to an increased hyper-
excitability state in the VLW model and found at 
elevated levels bound to Ago-2 was miR-134. 
MiR-134 has been shown to be increased fol-
lowing neuronal activity [44] and inhibition of 
miR-134 reduced the epileptic phenotype in 
mouse models of epilepsy [29, 53]. Finally, miR-
128, also strongly up-regulated in VLW mice, 
has also been shown to be implicated in hyper-
excitability states in the brain by suppressing 
the expression of various ion channels and sig-
naling components of the extracellular signal-
regulated serine/threonine kinase ERK2 with 
loss of miR-128 leading to fatal epilepsy [45]. 
Thus, increased miR-128 levels in the hippo-
campus may represent an attempt to oppose 
hyperexcitability states in VLW mice. This noti- 
ceable influence of tau pathology within the 
model on key miRNAs may have implications on 
the incidence of epileptic activity in tauopa-
thies such as AD, where an increased hyperex-
citability state is postulated as one of the key 
events driving pathology [52]. 
MiR-29b*, the sole downregulated miRNA iden-
tified in the profile, has intriguing implications 
within AD as a similar downregulation of miR-
29b* has previously been identified in AD 
patient brains [54]. Work using primary cell cul-
tures have provided evidence that miR-29b* 
targets and down regulates the β-secretase 
BACE1, the loss of miR-29b* regulation of 
BACE1 levels contributes to an increased pro-
duction of amyloid-β [54]. Thus, a downregula-
tion of miR-29* in the presence of pathological 
tau may indicate a novel mechanism by which 
hyperphosphorylation of tau contributes to 
β-amyloid build up in AD. 
A major limitation of our study is the low sample 
number used for Ago-2 miRNA profiling by 
OpenArray. This precluded meaningful statisti-
cal testing or correction for multiple compari-
sons. However, basing the selection of miRNAs 
on fold-change nevertheless resulted in repro-
ducible validation in subsequent miRNA-specif-
ic assays on individual independent samples. A 
further caveat of our study is that we performed 
validation of specific miRNAs using total rather 
than Ago-2-bound miRNA. However, previous 
data has demonstrated that Ago-2 miRNA 
loading correlates closely with the total expres-
sion of miRNAs [36]. Our findings support this, 
showing the OpenArray results closely correlat-
ed with levels of miRNA expression. Finally, 
there are several transgenic tau models, each 
showing different stages of pathology. Whereas 
the VLW model may be considered to be a mild 
model of tauopathy [24], other models such as 
the P301S tauopathy mouse model [34] show 
a much stronger phenotype and should be ana-
lyzed in future studies.
In conclusion, our results indicate that an over-
expression of pathological mutant tau leads to 
an increase in Ago-2 loaded miRNA, possibly 
leading to a reduction in protein translation and 
impacting on tau-induced pathology. 
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